Compare · GH secretagogue
CJC-1295 vs Tesamorelin
Both are gh secretagogue compounds. Here's how they line up on the evidence — graded the same way.
| CJC-1295 | Tesamorelin | |
|---|---|---|
| Evidence | Preliminary human | Strong human |
| Class | GH secretagogue | GH secretagogue |
| Summary | A long-acting GHRH analog that raises GH and IGF-1 in short human trials, but has no clinical-outcome data, is not FDA-approved, and is banned in sport. | Tesamorelin is an FDA-approved GHRH analogue with solid RCT evidence for shrinking visceral fat in HIV-associated lipodystrophy, but little proof outside that group. |
| Full profile → | Full profile → |
CJC-1295
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog designed to make the body secrete more of its own growth hormone (GH). Short human studies confirm it raises GH and IGF-1, but no trial has shown it changes any health or performance outcome, and no version is FDA-approved.
Tesamorelin
Tesamorelin, sold as Egrifta, is one of the few peptides in this space with genuine, FDA-grade human evidence behind it. The catch is that the evidence is almost entirely confined to one specific medical population, and a lot of how the compound is marketed elsewhere goes well beyond what those…